1-18 of 18
Boris Böll
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Nicola Goekbuget, Björn Steffen, Kathrin Nachtkamp, Boris Böll, Veit L. Buecklein, Christoph Faul, Jens Panse, Christoph Röllig, Folker Schneller, Bernd Spriewald, Matthias Stelljes, Max S. Topp, Andreas Viardot, Vladan Vucinic, Knut Wendelin, Monika Brüggemann, Monika Szczepanowski, Stefan Schwartz, Thomas Burmeister, Axel Benner, Nicholas Schreck, Lena Reiser, Hubert Serve, Walter Fiedler
Journal: Blood
Blood (2023) 142 (Supplement 1): 828.
https://doi.org/10.1182/blood-2023-179442
Published: 2023
Journal Articles

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Nicola Goekbuget, Walter Fiedler, Nael Alakel, Max S. Topp, Maher Hanoun, Björn Steffen, Ralph Wäsch, Andreas Viardot, Kathrin Nachtkamp, Matthias Stelljes, Hendrik Poeck, Vladan Vucinic, Boris Böll, Joachim Beck, Lars Fransecky, Knut Wendelin, Folker Schneller, Christoph Faul, Veit L Buecklein, Lena Reiser, Monika Brüggemann, Hubert Serve, Stefan Schwartz
Journal: Blood
Blood (2022) 140 (Supplement 1): 115–117.
https://doi.org/10.1182/blood-2022-158381
Published: 2022
Journal Articles

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Nicola Goekbuget, Matthias Stelljes, Andreas Viardot, Kathrin Nachtkamp, Björn Steffen, Folker Schneller, Nael Alakel, Max Topp, Boris Böll, Christoph Faul, Karsten Spiekermann, Knut Wendelin, Maher Hanoun, Ralph Wäsch, Joachim Beck, Sonja Martin, Vladan Vucinic, Claudia D. Baldus, Monika Brüggemann, Thomas Burmeister, Heike Pfeifer, Stefan Schwartz, Lena Baumann, Diana Tichy, Hubert Serve, Walter Fiedler
Journal: Blood
Blood (2021) 138 (Supplement 1): 362.
https://doi.org/10.1182/blood-2021-146306
Published: 2021
Journal Articles

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Bastian von Tresckow, MD, Andreas Hüttmann, MD, Vladan Vucinic, MD, Horst Mueller, PhD, Annette Plütschow, Andreas Viardot, MD, Max S. Topp, Carsten Kobe, MD, Boris Böll, MD, Dennis A. Eichenauer, Stephanie Sasse, MD, Heinz Haverkamp, Michael Fuchs, Andreas Engert, MD, Peter Borchmann, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2912.
https://doi.org/10.1182/blood-2018-99-117291
Published: 2018
Journal Articles

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group

Clinical Trials & Observations
Dennis A. Eichenauer, Annette Plütschow, Lena Schröder, Michael Fuchs, Boris Böll, Bastian von Tresckow, Volker Diehl, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2018) 132 (14): 1519–1525.
https://doi.org/10.1182/blood-2018-02-836437
Published: 2018
Journal Articles

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Clinical Trials & Observations Brief Report
Boris Böll, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Felicitas Hitz, Andrea Kerkhoff, Richard Greil, Bastian von Tresckow, Dennis A. Eichenauer, Carolin Bürkle, Sven Borchmann, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann
Journal: Blood
Blood (2016) 127 (18): 2189–2192.
https://doi.org/10.1182/blood-2015-11-681064
Published: 2016
Journal Articles

Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Dennis A. Eichenauer, MD, Helen Goergen, Annette Pluetschow, Karolin Behringer, MD, Stefanie Kreissl, MD, Paul Bröckelmann, MD, Michael Fuchs, MD, Boris Böll, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2015) 126 (23): 2729.
https://doi.org/10.1182/blood.V126.23.2729.2729
Published: 2015
Journal Articles

A Phase I Study of Everolimus in Combination with Time-Intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

Bastian von Tresckow, MD, Annette Pluetschow, Heinz Haverkamp, Vladan Vucinic, MD, Andreas Rank, MD, Max S. Topp, MD, Michaela Feuring-Buske, MD, Carsten Kobe, MD, Georg Kuhnert, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Michael Fuchs, MD, Andreas Engert, MD, Peter Borchmann, MD
Journal: Blood
Blood (2014) 124 (21): 4433.
https://doi.org/10.1182/blood.V124.21.4433.4433
Published: 2014
Journal Articles

Treatment of Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An Analysis from the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Annette Pluetschow, Michael Fuchs, MD, Karolin Behringer, MD, Boris Böll, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2014) 124 (21): 3058.
https://doi.org/10.1182/blood.V124.21.3058.3058
Published: 2014
Journal Articles

Doxorubicin, Vinblastine and Dacarbazine with or without Bleomycin for Older Patients with Early Stage Favorable Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials

Boris Böll, MD, Karolin Behringer, MD, Helen Görgen, Paul Bröckelmann, MD, Bastian von Tresckow, MD, Dennis A. Eichenauer, MD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD
Journal: Blood
Blood (2014) 124 (21): 3062.
https://doi.org/10.1182/blood.V124.21.3062.3062
Published: 2014
Journal Articles

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Clinical Trials & Observations
Dennis A. Eichenauer, Indra Thielen, Heinz Haverkamp, Jeremy Franklin, Karolin Behringer, Teresa Halbsguth, Beate Klimm, Volker Diehl, Stephanie Sasse, Achim Rothe, Michael Fuchs, Boris Böll, Bastian von Tresckow, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2014) 123 (11): 1658–1664.
https://doi.org/10.1182/blood-2013-07-512657
Published: 2014
Includes: Supplemental data
Journal Articles

Infradiaphragmatic Hodgkin Lymphoma In Patients Treated With State-Of-The-Art Therapies: A Risk Factor Analysis From The German Hodgkin Study Group (GHSG) HD13 and HD14 Trials

Bastian von Tresckow, MD, Helen Görgen, Annette Plütschow, PhD, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Achim Rothe, MD, Michael Fuchs, MD, Karolin Behringer, MD, Andreas Engert, MD, Peter Borchmann, MD
Journal: Blood
Blood (2013) 122 (21): 4231.
https://doi.org/10.1182/blood.V122.21.4231.4231
Published: 2013
Journal Articles

Impact Of Dose Reduction Of Bleomycin and Vincristine In Patients With Advanced Hodgkin Lymphoma Treated With Beacopp: A Comprehensive Analysis Of The German Hodgkin Study Group (GHSG) HD12 and HD15 Trials

Bastian von Tresckow, MD, Heinz Haverkamp, Boris Böll, MD, Dennis A. Eichenauer, MD, Stephanie Sasse, MD, Michael Fuchs, MD, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2013) 122 (21): 637.
https://doi.org/10.1182/blood.V122.21.637.637
Published: 2013
Journal Articles

German Hodgkin Study Group Phase I Trial Of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) For Older Hodgkin Lymphoma Patients

Boris Böll, MD, Annette Plütschow, PhD, Michael Fuchs, MD, Dennis A. Eichenauer, MD, Indra Thielen, MD, Bastian von Tresckow, MD, Karolin Behringer, MD, Johannes Atta, Michael Pfreundschuh, Prof, MD, Michaela Feuring-Buske, MD, Martin Vogelhuber, MD, Martin Sökler, MD, Andreas Engert, MD, Peter Borchmann, MD
Journal: Blood
Blood (2013) 122 (21): 3054.
https://doi.org/10.1182/blood.V122.21.3054.3054
Published: 2013
Journal Articles

Brentuximab vedotin for relapsed or refractory CD30 + hematologic malignancies: the German Hodgkin Study Group experience

Brief Report
Achim Rothe, Stephanie Sasse, Helen Goergen, Dennis A. Eichenauer, Andreas Lohri, Ulrich Jäger, Christopher Bangard, Boris Böll, Michael von Bergwelt Baildon, Sebastian Theurich, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2012) 120 (7): 1470–1472.
https://doi.org/10.1182/blood-2012-05-430918
Published: 2012
Journal Articles

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

Clinical Trials & Observations
Boris Böll, Henning Bredenfeld, Helen Görgen, Teresa Halbsguth, Hans T. Eich, Martin Soekler, Jana Markova, Ulrich Keller, Ullrich Graeven, Stephan Kremers, Michael Geissler, Guido Trenn, Michael Fuchs, Bastian von Tresckow, Dennis A. Eichenauer, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2011) 118 (24): 6292–6298.
https://doi.org/10.1182/blood-2011-07-368167
Published: 2011
Journal Articles

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

Brief Report
Dennis A. Eichenauer, Michael Fuchs, Annette Pluetschow, Beate Klimm, Teresa Halbsguth, Boris Böll, Bastian von Tresckow, Lucia Nogová, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2011) 118 (16): 4363–4365.
https://doi.org/10.1182/blood-2011-06-361055
Published: 2011
Journal Articles

Tipifarnib Is Cytotoxic and a Drug Transporter Inhibiting Chemosensitizer in Hodgkin Lymphoma Tumor Cells.

Boris Boll, MD, Anna Lang, Peer Langendorf, Hinrich P. Hansen, PhD, Elke P. von Strandmann, PhD, Andreas Engert, Bastian von Tresckow, MD
Journal: Blood
Blood (2007) 110 (11): 1386.
https://doi.org/10.1182/blood.V110.11.1386.1386
Published: 2007